These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118 [Abstract] [Full Text] [Related]
4. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Cochrane Database Syst Rev; 2013 Oct 17; 2013(10):CD003196. PubMed ID: 24132760 [Abstract] [Full Text] [Related]
13. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, Geddes J, Gilbody S, Palmer S, Woolacott N. Health Technol Assess; 2007 Oct 17; 11(39):iii-iv, ix-206. PubMed ID: 17903393 [Abstract] [Full Text] [Related]
14. Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis. Tarr GP, Glue P, Herbison P. J Affect Disord; 2011 Nov 17; 134(1-3):14-9. PubMed ID: 21145595 [Abstract] [Full Text] [Related]
18. Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium. Houston JP, Lipkovich IA, Ahl J, Rotelli MD, Baker RW, Bowden CL. J Psychiatr Res; 2007 Oct 17; 41(7):616-21. PubMed ID: 16236320 [Abstract] [Full Text] [Related]
19. GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. Young RC, Mulsant BH, Sajatovic M, Gildengers AG, Gyulai L, Al Jurdi RK, Beyer J, Evans J, Banerjee S, Greenberg R, Marino P, Kunik ME, Chen P, Barrett M, Schulberg HC, Bruce ML, Reynolds CF, Alexopoulos GS, GERI-BD Study GroupFrom the Department of Psychiatry and the Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, and New York Presbyterian Hospital, New York; the Department of Psychiatry, University of Toronto, and the Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland; the Department of Psychiatry, Louis Stokes Cleveland VA Medical Center, Cleveland; the Department of Psychiatry, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia; the Department of Psychiatry, Baylor College of Medicine, and the Michael E. DeBakey VA Medical Center, Houston; the Department of Psychiatry, Duke University Medical College, Durham, N.C.; and NIMH, Bethesda, Md.. Am J Psychiatry; 2017 Nov 01; 174(11):1086-1093. PubMed ID: 29088928 [Abstract] [Full Text] [Related]